Anti-Human LGALS1 (Clone CPTC-LGALS1-1) – Purified No Carrier Protein

SFVLNLGK

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

SAIC-25B-112 H1/L1 activity is directed against human galectin-1 (LGALS1) peptide sequence SFVLNLGK.

CPTC-LGALS1-1

Galectins are involved in a wide range of physiological processes, including pre-mRNA splicing, cell cycle progression, cell growth, apoptosis, pathogen recognition, antigen processing, leukocyte trafficking, and immune activation and suppression¹. Galectins primarily function by binding to the outermost group of carbohydrates on a glycoprotein or glycolipid oligosaccharide. However, in apoptosis, galectins function via protein-protein interaction. Galectins are often highly expressed at sites of inflammation and in the tumor microenvironment. LGALS1 encodes galectin-1, one of about 11 human galectins.

In normal cellular physiology, galectin-1 plays roles in cell growth, migration, adhesion, apoptosis, inflammation, immune response (including infection, transplantation, and autoimmunity), angiogenesis, axonal regeneration, nervous system development, immune tolerance in early pregnancy, and muscle differentiation¹. Additionally, intracellular galectin-1 functions as a splicing factor and is involved in intracellular signaling, whereas extracellular galectin-1 facilitates interactions between cells and other cells and/or the extracellular matrix. In pathological processes, galectin-1 is involved in tumor progression and evasion of cancer immune surveillance. Galectin-1 is of interest as a potential biomarker for cancer diagnosis and prognosis and as a target of cancer therapeutics².

SAIC-25B-112 H1/L1 was generated in rabbit for use in immuno-MRM assays using a synthetic peptide derived from human LGALS1, SFVLNLGK³. SAIC-25B-112 H1/L1 can also detect LGALS1 by indirect ELISA⁴. SAIC-25B-112 H1/L1 does not detect LGALS1 by immunohistochemistry, immunofluorescence, or Western blotting.

Galectin-1 is expressed in a wide range of tissues and cell types and has broad localization to the nucleus, cytoplasm, cell surface, and extracellular space. Galectin 1 can also be secreted across the plasma membrane using an unconventional protein secretion pathway.

LGALS3BP, beta-galactoside and other complex carbohydrates

1 Yu X, Qian J, Ding L, et al. Int J Mol Sci. 24(7):6501. 2023.
2 Nerella SG. Eur J Med Chem. 11:100170. 2024.
3 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
4 https://antibodies.cancer.gov/detail/CPTC-LGALS1-1